• Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patients
• With the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation.
• 47% of adults live with hypertension but only 24% of them have it under control
• With its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030

Lexaria Bioscience (NASDAQ: LEXX), a global leader in enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is looking to push the conversation about high blood pressure. Lexaria continues to move forward, most recently with the success in its latest human clinical study, HYPER-H21-4. The study may be the first to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM) technology (https://ibn.fm/cB22n). Since Lexaria began developing DehydraTECH in 2014, it has continued to strengthen and broaden the technology, exploring various areas including but not limited to the oral administration of antivirals, cannabinoids, vitamins, nicotine, and PDE5 inhibitors. In early 2021, it began dosing in its first human clinical study that assessed its DehydraTECH-enabled CBD capsule formulation. This would lay the groundwork for subsequent studies while also bolstering the company’s growing list of patents, which currently stands at 27, spread across the world, including the use of DehydraTECH-processed CBD for the treatment of heart disease (https://ibn.fm/Nd0Hf). Lexaria is working toward an Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval. It hopes to build on the success of the studies so far to enhance its understanding of DehydraTECH-CBD for treating cardiovascular and other disease states beyond hypertension. Since its inception, Lexaria has been committed to addressing severe unmet patient needs. Hypertension has been one of the company’s main focus areas, with 47% of adults living with the condition, but only 24% have it under control. Through its research, it looks to address the condition, ultimately tapping into a market projected to post a CAGR of 3.4% between 2022 and 2030 to hit $34 billion in value (https://ibn.fm/3PBED). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Nearly a decade has passed since the Paris Accords established international cooperation on curbing fossil fuel pollutants believed to be responsible for adversely affecting the earth’s climate, and some agencies worry that not enough is happening to meet the accords’ goals
• Despite concerns about obstacles to renewable energy adoption, the same agencies note that investment in climate-friendly technologies is rising
• Correlate Infrastructure Partners is a U.S.-based company works with the commercial real estate industry to drive the transition to climate-friendly energy sources, helping clients analyze their utilities use, identifying ways to improve their ESG outcomes, and presenting funding opportunities to make cleaner energy an easy-to-afford part of their operational reality

Clean energy solutions innovator Correlate Infrastructure Partners (OTCQB: CIPI) is helping to move the needle on greenhouse gas reduction by advising the commercial real estate industry (companies that develop and rent out commercial building properties) on ways to transition to more climate-friendly utilities in their operations and on ways to make such transitions cost-effective. Worldwide, governments and private industries continue increasing their emphasis on clean energy adoption and reduction of their reliance on fossil fuels amid reports of an upward trend in extreme weather events and the insecurity people face in finding food and housing as a result (https://ibn.fm/CIT3i). Nearly a decade after nearly 200 international political governments and environmental activists arrived at a United Nations-sponsored agreement to limit pollutants believed responsible for a rising number of climate change-spawned extreme weather events, The United Nations is bemoaning a lack of effective progress on achieving the Paris Climate Accord goals (https://ibn.fm/r8zps). Uncertainty by European regulators over tax and subsidize the energy industry to quell high prices (https://ibn.fm/JDe5K) are likewise leading to fears that investment in renewable energy may decrease at a time when climate-friendly technologies are just beginning to take off on the continent (https://ibn.fm/6fbPU). The International Energy Agency (“IEA”), a Paris-based intergovernmental organization focused on policy advisement for energy security worldwide, reported earlier this year that global energy investment is expected to increase by 8 percent this year to $2.4 trillion. Those investments are primarily in clean energy operations, but the IEA report echoed the United Nations’ assessment that the pace is insufficient to address climate concerns (https://ibn.fm/vb7oA). Still, an Oct. 20 Scientific American report analyzing data from the IEA and other sources found reasons for optimism in the overall accomplishments of renewable energy transitioning, which would include the work Correlate Infrastructure and its subsidiaries are doing with their clients. Citing an IEA report that global carbon dioxide emissions associated with energy use are on track to increase 1 percent this year, Scientific American noted the 1 percent increase is “significantly less than what many observers projected earlier this year” when surging natural gas prices worldwide led to worries pollution-emitting coal use would also surge. “Just peaking global emissions is the first and easiest step on the road to solving climate change,” Zeke Hausfather, a climate researcher at the payment processing firm Stripe, stated in the report, adding that global emissions are likely to plateau in the coming years while decarbonization trends keep pace with economic growth (https://ibn.fm/LCVbh). The IEA reports the growth of renewable energy has “consistently and dramatically” outperformed nearly all expectations over the past decade, making it necessary for analysts to continually revise their projections for the future (https://ibn.fm/gYtcX). While coal consumption has increased this year, “the emissions impact has been largely offset by record setting growth in renewables,” the IEA informed Scientific American. Not only is it a sign that decarbonization policies are driving structural change, but “those changes are set to accelerate thanks to the major clean energy policy plans that have advanced around the world in recent months,” IEA Executive Director Fatih Birol stated. Correlate Infrastructure Partners is driven to help clients break down barriers to their environmental, social and governance (“ESG”) goals while demonstrating that sustainability and profitability are no longer at odds in terms of corporate aims. For more information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• The U.S. Federal Trade Commission is increasingly seeking to protect the online privacy rights of consumers
• The FTC recently sued data broker Kochava for brokering the geolocation details of millions of consumers
• Texas Attorney General Ken Paxton has filed suit against Google for allegedly collecting customer information without consent
• Reklaim enables users to reclaim their data – providing the option to delete it or monetize it

A poll conducted during the summer of 2021 showed that 13 percent of UK teens and 6 percent of American teens linked Instagram usage to suicidal thoughts. Even more surprising is the fact that the social media platform was seemingly privy to that knowledge all along. The extent to which Instagram parent company Meta (NASDAQ: META) allegedly knew about the harmful effects of its products and withheld that information from the public caused Senator Richard Blumenthal (D-CT) to compare the company’s tactics to those of tobacco companies in years past (https://ibn.fm/tPQr2). The allegations have also sparked a spate of legislation, with a number of senators recently approaching the Federal Trade Commission (“FTC”) to update the Children’s Online Privacy Protection Act in a move intended to oblige social media platforms to protect the confidentiality, security and integrity of data relating to minors. Reklaim (TSX.V: MYID) (OTCQB: MYIDF), a business focused on enabling consumers to reclaim their online information and monetize it, has been at the forefront of the battle to assist and empower users to establish ownership over personal data which has, in many cases, been circulating in the market unbeknownst to them. The company’s actions have encountered renewed impetus given increased focus on protecting data privacy from the FTC and its ongoing initiatives toward making online privacy a priority. The Advanced Notice of Proposed Rulemaking (“ANPR”) – opened by the FTC for public comments over the summer – is the first stage of that process, as noted by Rashida Richardson, the attorney advisor to FTC Chair Lina Khan, at AdExchanger’s Programmatic IO conference in New York City. “We have to go aggressively after [high-risk] data practices that pose the greatest risks to consumers, at least as a mitigating intervention,” Richardson said (https://ibn.fm/N8jHA). The FTC’s push was in full effect when the agency sued Idaho-based data broker Kochava for selling the geolocation data of hundreds of millions of mobile devices – data which the FTC argues could be used to track the physical location of consumers, including to and from sensitive areas such as reproductive health clinics or churches (https://ibn.fm/CfSyV). The litigation against Kochava coincides with a separate lawsuit filed by Texas AG Ken Paxton against Google for allegedly collecting and using biometric data belonging to millions of Texans without proper consent. The legal action has drawn attention both for the scale of the motion’s defendant and for the implications it could have on the behavior of other online businesses operating throughout the nation. With Reklaim, not only are consumers able to unlock the online data collected on them, they are able to preclude the data from leaking from their devices in the first place – the latter scenario being one which has long been exploited by search engines, social media platforms and online data brokers alike. Rather, should they wish, consumers are empowered to monetize their data, gaining compensation in return for providing third-party businesses with insights drawn from their online behavior. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• 2021 represented the first time in half a century that large urban counties experienced negative growth
• Migration to suburbs and exurban counties contribute more to carbon emissions, highlighting the need for a transition to renewable energy to combat climate change
• GeoSolar Technologies is an emerging leader with its whole-home system using solar, geothermal, and proprietary air filtration technologies

Americans in 2021 exited urban counties in droves, heading for suburban and exurban counties at a record pace. From an environmental perspective, the transition can have unintended negative consequences, as people generally have more property outside the city, drive more, and use more energy. It doesn’t haven’t to be that way, though, with net-zero pioneers like Norbert Klebl, Co-Founder, Development Director of GeoSolar Technologies (“GST”), leading a charge to rethink how suburban homes are powered, heated, and cooled with renewable resources. According to the Economic Innovation Group using federal statistics, large urban counties (defined as those with 250,000+ people that include an urban center) experienced a net loss of 863,000 residents in 2021. A stunning 68% of these large urban counties shed population during the year, leading to the first time in 50 years that the aggregated group experienced negative growth. The suburbs increasingly becoming the popular place to live has put an emphasis on the need for a clear focus on building the communities more sustainably. In a bid to slash carbon dioxide emissions in the coming years with a goal of net zero as early as 2050, cities nationwide are adopting stringent regulations. This summer, Crested Butte, Colorado banned natural gas use in new construction, joining cities and counties in California and New York City with similar laws. Now, Louisville, Colorado is looking to be the second city in the state to force electrification in new construction, a sign of an emerging trend in the mountainous state. As Klebl noted in a recent Fortune article, there are many challenges related to the implementing net zero processes, including educating planning officials, contractors, and subcontractors. Klebl, recognized as one of the leading zero-carbon experts in the world, is now devoting his time to GeoSolar Technologies, a Denver-based climate technology company and creator of the SmartGreen™ Home system for newly built and existing homes and commercial buildings. Geothermal and solar technologies are the backbone of SmartGreen™ Homes, which can operate completely disconnected from the electric grid and without the need to any fossil fuels. The patent-pending integrated system captures energy from the sun via rooftop photovoltaic solar panels for the home’s electricity demand. All appliances and mechanicals are electric and GeoSolar has options for electric car charging stations. Geothermal systems involve using the near constant temperature of the earth only a few feet underground for efficient heating and cooling in combination with a proprietary air purification unit that captures disease and illness-carrying pathogens. GeoSolar has outfitted several test homes in Colorado for analysis where it has demonstrated some of the best results in the industry as measured by the Home Efficiency Ratings System (“HERS”). For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• The manufacture of lower cost electric vehicles is conditional on the decrease of component costs, with battery packs forming one of the largest parts of their cost structure
• Hillcrest Energy Technologies’ revolutionary inverter technology, which forms an integral part of an electrical vehicle’s powertrain, allows EV’s to improve thermal management and reduce switching losses
• Improved power quality resulting from more efficient power inverters can enable automakers to obtain higher powertrain efficiency and consequently, reduce their battery packs
• Hillcrest Energy Technologies separately seized the opportunity to announce the appointment of Samuel Yik as their new CFO

One of the world’s most inexpensive electric vehicles, the Changli Freeman, currently has a listing price of approximately $1,000. It weighs 323 kilograms, packs up to a 1.2 kW motor, can reach 35km/h and has a claimed range of 40-100 kilometers (https://ibn.fm/ay2wL). By contrast and as of 2018, a Tesla Model 3’s inverter alone was estimated to cost the manufacturer upwards of $1,100 per unit. Hardware costs have come down dramatically in ensuing years; as of 2020, a Model Y inverter was reported to cost approximately $700 per unit, a $400 reduction relative to the 2018 Model 3 version. Nevertheless, component costs remain a key constraint to the further reduction of automotive manufacturing costs, a challenge which Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) is seeking to take on. Hillcrest Energy Technologies, a clean technology company focused around developing transformative power conversion technologies, has centered its energies on creating solutions which have the potential to unlock efficiencies in electrification and maximize the performance of integrated electric systems. “While we have a focus on traction inverter technology for electric vehicles (‘EVs’), the technologies we are developing can also be applied to a wide range of industries to make electrical systems more efficient,” said Hillcrest Chief Technology Officer Ari (https://ibn.fm/Imzjh). In effect, Hillcrest’s revolutionary technology seeks to eliminate traditional design tradeoffs faced across the power industry – in which deploying higher switching frequencies has historically resulted in a greater increase in losses. Since Hillcrest’s inverter technology materially eliminates switching losses, it makes higher switching frequencies feasible, enabling improved output power quality and a reduction in DC-link capacitor size. In turn, this can assist electric vehicle manufacturers by enabling them to reduce motor size, lower torque ripple, and benefit from the increased lifespan of mechanical parts utilized within their traction applications. Over the years, electric vehicle manufacturers have been subject to an accelerated version of Moore’s Law. By some accounts, it costs Tesla $84,000 to manufacture a single vehicle as of 2017 – a cost which has been since been reduced to a reported $36,000 (https://ibn.fm/D3vZ5). Whilst inverters account for less than 2 percent of the total manufacturing cost, they are a crucial component within EV powertrains; a more efficient and lighter inverter could drive cost reductions within the overall battery pack cost structure. Moreover, and with battery systems currently the single most expensive element within most EVs, the manufacture of lower-cost, high-performance battery packs are key to producing affordable electric cars that can go toe to toe with combustion-engine rivals on sticker prices. With Tesla for instance, CEO Elon Musk’s promised improvements in battery cost – which he has pledged to more than half – are seen by investors as critical to the automaker’s quest to usher in an era where it can sell a $25,000 EV for a profit. Hillcrest Energy Technologies has positioned itself and its revolutionary product suite to form part of the cornerstone for the upcoming generation of electric vehicles. As part of its ongoing evolution, Hillcrest recently announced the appointment of Samuel Yik as the company’s Chief Financial Officer (“CFO”). Yik, a Chartered Professional Accountant by training, brings over 10 years of CFO experience in managing publicly listed companies in Canada and the United States and will be instrumental towards contributing to Hillcrest Energy’s future success. “We look forward to having Samuel’s skill and experience on our team,” said Don Currie, CEO of Hillcrest. “We anticipate an acceleration of our progress over the coming year, and Samuel’s extensive knowledge coupled with his ‘can do’ attitude and team-based approach will be key to our continued success.” For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

• BiondVax has an exclusive worldwide license to commercialize NanoAbs for the treatment of COVID-19
• The company plans to initiate a Phase 1/2a clinical trial of its inhaled COVID-19 therapeutic NanoAb in 2023
• BiondVax has exclusive options for worldwide licenses for NanoAbs to treat other disorders with large, underserved needs
• The company has filed a Registration Statement with the SEC for an underwritten offering of shares

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

• NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems
• The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process
• Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease
• Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure
• The concussion therapeutic solution recently completed Phase I testing successfully and the company is preparing for Phase II efficacy testing in cooperation with military service personnel

Medical technology solutions innovator Odyssey Health (OTC: ODYY) is moving up a rung on the ladder to product success with the formation of a wholly owned pharmaceutical subsidiary focused on developing drugs to treat neurological disorders. Odyssey has been developing and testing drug candidates to combat conditions with unmet needs, with primary area of interest being the development of drug and device combination products that will help people afflicted by central nervous system maladies. This area includes brain concussions, especially affecting military and sports personnel, in addition to a neurological disease with a high mortality rate among pediatric patients, and potentially deadly exposure to nerve gas agents. In September, Odyssey reported completion of its Phase I clinical trial for its concussion drug candidate, PRV-002. The safety trial’s Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) cohorts all found the drug to be well tolerated, and Odyssey is now communicating the trial’s findings to the U.S. Food and Drug Administration (“FDA”) while beginning preparations for a Phase II trial that will seek to provide greater evidence of the drug’s effectiveness, according to a company news release (https://ibn.fm/LpDXa). The new subsidiary, Odyssey Neuropharma, Inc., will help advance Odyssey’s development of neurosteroids such as PRV-002 and PRV-001, which is being designed to combat the neuro-degenerative Niemann-Pick type C disease and has been shown to improve neuromotor function and reduce brain inflammation in pre-clinical studies, according to the company’s most recent news release (https://ibn.fm/dtIcz). Both drugs are fully synthetic and are administered via a breath-powered intranasal delivery device subject to a provisional patent application. The Organophosphate Nerve Agent antidote similarly involves intranasal delivery of powdered oximes (a class of nitrogen-containing organic compounds) to combat the consequences of exposure to chemical weapons. Current use of oximes as an antidote involves multiple injections but Odyssey’s attempt to develop an intranasal product offers the hope of a painless means of delivery that is fast-acting and targeted to the central nervous system. “Odyssey’s lightweight drug device combination can be carried in the pocket of civilians around the world at risk (of nerve agent exposure) as a means of biodefense,” the company’s news release states. Odyssey has also produced other products for potential commercial marketability, such as a device to remove a throat obstruction in a choking person and new technology for the early detection for heart disease. Each product furthers the company’s mission to develop products that fill needs for life-saving solutions to acute brain, cardiovascular and respiratory emergencies. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern Colombia
• Flora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprint
• FGH is focused on the German market, where its subsidiary was the first company to sell cannabis
• Germany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of Europe’s cannabis sales
• Flora has already reported cooperative agreements to increase its product distribution pipeline to Switzerland and the Czech Republic

Cannabis cultivator, brand manufacturer and global distributor Flora Growth (NASDAQ: FLGC) is aiming for continued revenue boosts through strategic acquisitions, announcing Oct. 24 that it will obtain the issued and outstanding shares of multi-national operator Franchise Global Health Inc. as the company positions itself to expand its wholesale cannabis sales and brand distribution operations in Europe. The company stated in its news release that it expects the acquisition to result in at least $3 million of annualized cost synergies within the first year as they eliminate repetitive costs between the two companies (https://ibn.fm/NSGY6). Both companies expect to announce their Q3 financial reports in the near future and while the announcement doesn’t otherwise provide projections of their future performance, Flora’s acquisition strategy has injected significant revenue in recent months, such as when it announced that H1 revenues grew 604 percent YOY to about $15 million (https://ibn.fm/G9uQZ). Flora and Franchise Global Health (stylized FGH) expect to close the all-stock deal in December following presentation of the agreement to FGH shareholders for a vote. “At Flora, we believe that cannabis will dramatically improve the wellbeing of consumers around the globe and that it will become an international trade. Our company exists today to capitalize on that opportunity,” CEO Luis Merchan stated in a video interview about the agreement (https://ibn.fm/JfhPz). “Together we have a very sustainable business,” FGH CEO Clifford Starke stated during the interview. “We have extremely strong revenue performance without executing on really what we’re trying to do, which is become a fully integrated medical cannabis company of high THC products.” One of Flora Growth’s strategic acquisitions earlier this year was consumer wellness brand JustCBD, which increased Flora’s profile to more than half a million wellness consumers and 14,000 points of distribution in the United States at the time. JustCBD’s 79 products registered with the UK’s novel foods standards agency are expected to also help the company expand its operational footprint in Europe and the United Kingdom where CBD is still nascent. Within the United States the company’s NASDAQ listing precludes Flora from participating in the THC (traditional tetrahydrocannabinol cannabis) market however Flora does provide THC and CBD flower and derivatives to international markets thanks to its strong position with a licensed cultivation, extraction and isolation facility in northern Colombia’s fertile climate. FGH was the first company to sell cannabis in Germany, and the companies perceive Germany as they key to entering the rest of Europe. “Our full focus is on Germany,” Starke said. “Our strong position is on the distribution front. … Which, if this cannabis market is going to come to life, which we all believe so, … we’re extremely well positioned to go past Germany into the rest of Europe. It’s very important to understand that 75 to 80 percent of the sales in Europe are accounted in Germany.” Starke added that the acquisition will fill FGH’s strongest need — supply of cannabis. Given Flora’s Colombian cultivation and cost advantages and FGH’s existing relationships with more than 1,200 pharmacies, the companies believe they are well suited to lead the way in medical cannabis in Germany. “When we started up in Germany and going into 2019, we were selling 60, 70, 80 kgs a month quite easily, and unfortunately supply constraints really limited us and now we’re back on path to regain market share,” he said. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause
• Lexaria’s patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing
• The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026

In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to the Centers for Disease Control and Prevention (“CDC”), in 2020, more than 670,000 deaths in the United States had high blood pressure as a primary or contributing cause (https://ibn.fm/bMiDk). Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced that its human clinical study HYPER-H21-4 may be the world’s first study to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company’s patented DehydraTECH(TM)-enabled CBD capsule formulation. According to company CEO Chris Bunka, this is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit. Additionally, DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study (https://ibn.fm/EJuhp). “Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD,” Bunka added. “Consistent with Lexaria’s often-mentioned de-risking strategy, this exceptional safety profile should prove beneficial as we prepare for our planned upcoming Phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.” The primary safety and efficacy objectives of the HYPER-H21-4 study were achieved, with a significant reduction in blood pressure achieved in 2.5 weeks and over the course of the five weeks of dosing. During the trial, zero serious adverse events were reported. No adverse changes were observed in liver enzymes, which is an important clinical safety biomarker of oral CBD therapy. The study notes that a significant blood pressure decrease was achieved using relatively low doses of DehydraTECH-CBD, a key indicator of the well-established drug delivery efficiencies of the company’s technology – with superior power evidenced through its unique formulation to reduce blood pressure over other oral CBD formulation (https://ibn.fm/fY5jY). The positive findings emphasize Lexaria’s unique position to address the unmet needs of the growing antihypertension drug market. The industry was responsible for $22,557 million in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in $28,797 million by 2026 (https://ibn.fm/JfkSc). Lexaria’s DehydraTECH technology was designed for formulating and delivering lipophilic drugs and active ingredients. It increases effectiveness and improves how active pharmaceutical ingredients (“APIs”) enter the bloodstream. The benefits of Lexaria’s DehydraTECH technology include the following:

• Speeds up the delivery so that effects are felt in minutes
• Increased bioavailability
• Increased brain absorption
• Improves drug potency
• Reduces drug administration costs so that lower doses are necessary
• Masks unwanted taste, eliminating and reducing the need for sweeteners

Since 2016, Lexaria has demonstrated, through its DehydraTECH technology, the ability to increase bio-absorption by up to five to ten times. It has reduced the onset time from one to two hours to just minutes. It will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, nicotine and more. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder
• Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery
• Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently evaluating the company’s novel therapeutic, designated as SPC-14. Silo first entered a sponsored pact with the university in October 2021 and has recently extended the agreement to continue research for SPC-14 and SPC-15, the company’s therapeutic for stress-induced anxiety disorders (https://ibn.fm/aplTY). “The first steps of our research with Columbia have been positive and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer’s therapeutic and SPC-15 for Stress-Induced Anxiety disorders,” said Silo CEO Eric Weisblum. The agreement extension incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at the Columbia University Irving Medical Center. With a focus on the molecular mechanisms underlying learning and memory, Dr. Denny’s research aims to uncover whether ketamine and the novel inventions possibly licensed by Silo can improve memory retrieval, halt, or even reverse the disease process. Silo additionally funds researchers at the Translational Psychedelic Program at the University of California San Francisco (“USCF”) to study the effects of psilocybin on various inflammatory conditions. UCSF researchers are aiming to identify the effects of psilocybin on inflammatory markers of the disease. The study recently passed a significant milestone where patients were successfully dosed and blood samples were collected (https://ibn.fm/oo8Qk). Silo Pharma aims to differentiate its treatments through enhanced delivery mechanisms that improve efficacy while reducing side effects. The company formulations leverage proprietary Z-pod(TM) technology developed by partner Zylö Therapeutics that use highly engineered amorphous silica particles that encapsulate compounds to improve treatment performance. Preclinical studies demonstrated that the jointly developed delivery method and formulation can hold and distribute therapeutics in a time-released manner to provide targeted delivery, increased bioavailability (https://ibn.fm/tliga). Silo Pharma Inc. is fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, rheumatoid arthritis, and other rare neurological disorders. The company partners with leading institutions such as Columbia University, the University of California San Francisco (“UCSF”), and the University of Maryland, Baltimore (“UMB”) to develop treatments the company believes will transform healthcare and improve patient outcomes. For more information, visit the company’s website at www.SiloPharma.com. NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO